Truist analyst Asthika Goonewardene lowered the firm’s price target on BioNTech (BNTX) to $151 from $172 and keeps a Buy rating on the shares.

In a report released today, Chris Shibutani from Goldman Sachs maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

In a report released today, Eliana Merle from UBS maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target of ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...

TD Cowen lowered the firm’s price target on BioNTech (BNTX) to $110 from $122 and keeps a Hold rating on the shares. The firm updated its model ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...

BMO Capital analyst Etzer Darout raised the firm’s price target on BioNTech (BNTX) to $143 from $130 and keeps an Outperform rating on the ...